Cancer Cell International (Dec 2022)

Regulation of mitochondrial complex III activity and assembly by TRAP1 in cancer cells

  • Danilo Swann Matassa,
  • Daniela Criscuolo,
  • Rosario Avolio,
  • Ilenia Agliarulo,
  • Daniela Sarnataro,
  • Consiglia Pacelli,
  • Rosella Scrima,
  • Alessandra Colamatteo,
  • Giuseppe Matarese,
  • Nazzareno Capitanio,
  • Matteo Landriscina,
  • Franca Esposito

DOI
https://doi.org/10.1186/s12935-022-02788-4
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 18

Abstract

Read online

Abstract Background Metabolic reprogramming is an important issue in tumor biology. A recently-identified actor in this regard is the molecular chaperone TRAP1, that is considered an oncogene in several cancers for its high expression but an oncosuppressor in others with predominant oxidative metabolism. TRAP1 is mainly localized in mitochondria, where it interacts with respiratory complexes, although alternative localizations have been described, particularly on the endoplasmic reticulum, where it interacts with the translational machinery with relevant roles in protein synthesis regulation. Results Herein we show that, inside mitochondria, TRAP1 binds the complex III core component UQCRC2 and regulates complex III activity. This decreases respiration rate during basal conditions but allows sustained oxidative phosphorylation when glucose is limiting, a condition in which the direct TRAP1-UQCRC2 binding is disrupted, but not TRAP1-complex III binding. Interestingly, several complex III components and assembly factors show an inverse correlation with survival and response to platinum-based therapy in high grade serous ovarian cancers, where TRAP1 inversely correlates with stage and grade and directly correlates with survival. Accordingly, drug-resistant ovarian cancer cells show high levels of complex III components and high sensitivity to complex III inhibitory drug antimycin A. Conclusions These results shed new light on the molecular mechanisms involved in TRAP1-dependent regulation of cancer cell metabolism and point out a potential novel target for metabolic therapy in ovarian cancer.

Keywords